Hyaluronic acid: A unique topical vehicle for the localized delivery of drugs to the skin

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 3, 2005, Pages 308-318

  Brown, Marc B ^a   Jones, S A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Actinic keratoses; Dermatology; Diclofenac; Hyaluronic acid; Solaraze; Topical drug delivery

Indexed keywords

ACECLIDINE; ARECAIDINE; BIOMATERIAL; COSMETIC; DICLOFENAC; DOXORUBICIN; FILLER; FLUOROURACIL; GENTAMICIN; GLUCURONIC ACID; HYALURONIC ACID; INSULIN; MONOCLONAL ANTIBODY; N ACETYLGLUCOSAMINE; PACLITAXEL; PILOCARPINE; PLASMID DNA; POLYANION; POLYSACCHARIDE; SOMATOMEDIN; SUPEROXIDE DISMUTASE; TIMOLOL; TOBRAMYCIN; TROPICAMIDE; VASOPRESSIN; XYLOMETAZOLINE;

ACTINIC KERATOSIS; ARTHRITIS; BIOCOMPATIBILITY; CANADA; CHEMICAL STRUCTURE; CONNECTIVE TISSUE; COST EFFECTIVENESS ANALYSIS; CRYOSURGERY; DRUG ADMINISTRATION ROUTE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EUROPE; EYE SURGERY; HUMAN; IMMUNOGENICITY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SKIN ABRASION; SYNOVIAL FLUID; TISSUE REGENERATION; UNITED STATES; VERTEBRATE; VISCOELASTICITY; WOUND HEALING;

ADMINISTRATION, CUTANEOUS; COSMETICS; HUMANS; HYALURONIC ACID; VEHICLES;

EID: 18844423259     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.01180.x     Document Type: Review

References (158)

1. Meyer L, Palmer J. The polysaccharide of the vitreous humour. Biol Chem 1934; 107: 629-634.
2. Laurent TC. Structure of hyaluronic acid. In: Balazs EA, ed. Chemistry and the Molecular Biology of the Intracellular Matrix. Academic Press, London, 1970: 703-732.
3. Milas M, Rinaudo M, Roure I et al. Comparative rheological behavior of hyaluronan from bacterial and animal sources with cross-linked hyaluronan (hylan) in aqueous solution. Biopolymers 2001; 59: 191-204.
4. Larsen NE, Balazs EA. Drug delivery systems using hyaluronan its derivatives. Adv Drug Dev Rev 1991; 7: 279-293.
5. Denlinger JL. Hyaluronan and its derivatives as viscoelastics in medicine. In: Laurent TC, ed. The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives. Portland Press, London, 1998: 235-242.
6. Band PA. Hyaluronan derivatives: chemistry and clinical applications. In: Laurent TC, ed. The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives. Portland Press, London, 1998: 33-42.
7. Lapcik L, Lapcik L, De Smedt S, et al. Hyaluronan: preparation, structure, properties, applications. Chem Rev 1998; 98: 2663-2684.
8. Vercruysse KP, Prestwich GD. Hyaluronate derivatives in drug delivery. Crit Rev Ther Drug Carrier Syst 1998; 15: 513-555.
9. Adams ME, Lussier AJ, Peyron JG. A risk-benefit assessment of injections of hyaluronan and its derivatives in the treatment of osteoarthritis of the knee. Drug Saf 2000; 23: 115-130.
10. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action. Arthritis Res Ther 2003; 5: 54-67.
11. Campoccia D, Doherty P, Radice M et al. Semi-synthetic restorable materials from hyaluronan esterification. Biomaterials 1998; 19: 2101-2127.
12. Laurent TC, Fraser JRE. Hyaluronan. FASEB J 1992; 6: 2397-2404.
13. Scott JE, Heatley F. Hyaluronan forms specific stable tertiary structures in aqueous solution: a C-13 NMR study. Proc Natl Acad Sci USA 1999; 96: 4850-4855.
14. Gribbon P, Heng BC, Hardingham TE. The analysis of intermolecular interactions in concentrated hyaluronan solutions suggest no evidence for chain-chain association. Biochem J 2000; 350: 329-335.
15. Gibbs DA, Merrill EW, Smith KA, Balazs EA. Rheology of hyaluronic acid. Biopolymers 1968; 6: 777-791.
16. Karim S, Brown MB, Ingham S, et al. Rheological and molecular weight studies of hyaluronan. Eur J Pharm Sci 1996; 4: S175.
17. Kobayashi Y, Okamoto A, Nishinari K. Viscoelasticity of hyaluronic-acid with different molecular-weights. Biorheology 1994; 31: 235-244.
18. Fujii K, Kawata M, Kobayashi Y, et al. Effects of the addition of hyaluronate segments with different chain lengths on the viscoelasticity of hyaluronic acid solutions. Biopolymers 1996; 38: 583-591.
19. PasqualiRonchetti I, Quaglino D, Mori G, et al. Hyaluronan-phospholipid interactions. J Struct Biol 1997; 120: 1-10.
20. Mo Y, Takaya T, Nishinari K, et al. Effects of sodium chloride, guanidine hydrochloride, and sucrose on the viscoelastic properties of sodium hyaluronate solutions. Biopolymers 1999; 50: 23-34.
21. Ghosh P, Hutadilok N, Adam N, Lentini A. Interactions of hyaluronan (hyaluronic-acid) with phospholipids as determined by gel-permeation chromatography, multi-angle laser-light-scattering photometry and H-1-Nmr spectroscopy. Int J Biol Macromol 1994; 16: 237-244.
22. Koshiishi I, Horikoshi E, Imanari T. Quantification of hyaluronan and chondroitin/dermatan sulfates in the tissue sections on glass slides. Anal Biochem 1999; 267: 222-226.
23. Poggi MM, Klein MB, Chapo GA, Cuono CB. Effects of cryopreservation and deconstruction on the dermal glycosaminoglycan content of human skin. J Burn Care Rehabilitation 1999; 20: 201-206.
24. Juhlin L. Hyaluronan in skin. J Intern Med 1997; 242: 61-66.
25. Tammi R, Agren UM, Tuhkanen AL, Tammi M. Hyaluronan metabolism in skin - introduction. Prog Histochem Cytochem 1994; 29: 1-77.
26. Banks J, Kreider JW, Bhavanadan VP, Davidson EA. Anionic polysaccharide production and tyrosine activation in cultured human melanoma cells. Cancer Res 1976; 36: 424-431.
27. Laurent TC. An early look at macromolecular crowding. Biophys Chem 1995; 57: 7-14.
28. Sakai S, Yasuda R, Savo T, et al. Hyaluronan exists in the normal stratum corneum. J Invest Dermatol 2000; 114: 1184-1187.
29. Tool BP. Hyaluronan in morphogenesis. Semin Cell Dev Biol 2001; 12: 79-87.
30. Pasonen-Seppanen S, Tammi R, Tammi M et al. Hyaluronan metabolism and distribution in stratified, differentiated cultures of epidermal keratinocytes. In: Kennedy J, Phillips GO, Williams PA, Hascall V, eds. Hyaluronan: Biomedical, Medical and Clinical Aspects. Woodhead Publishers, Cambridge, 2002: 511-516.
31. Banerji S, Ni J, Wang SX et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999; 144: 789-801.
32. Knudson W, Chow G, Knudson CB. CD44-mediated uptake and degradation of hyaluronan. Matrix Biol 2002; 21: 15-23.
33. Laugier JP, Shuster S, Rosdy M et al. Topical hyaluronidase decreases hyaluronic acid and CD44 in human skin and in reconstituted human epidermis: evidence that hyaluronidase can permeate the stratum corneum. Br J Dermatol 2000; 142: 226-233.
34. Isacke CM, Yarwood H. The hyaluronan receptor, CD44. Int J Biochem Cell Biol 2002; 34: 718-721.
35. Goodison S, Urquidi V, Tarin D. CD44 cell adhesion molecules. J Clin Pathol-Mol Pathol 1999; 52: 189-196.
36. Tammi MI, Day AJ, Turley EA. Hyaluronan and homeostasis: a balancing act. J Biol Chem 2002; 277: 4581-4584.
37. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J Rheumatol 1993; 20: 3-9.
38. Balazs EA, Denlinger JL. Clinical uses of hyaluronan. Ciba Found Symp 1989; 143: 265-280.
39. Hochberg MC. Role of intra-articular hyaluronic acid preparations in medical management of osteoarthritis of the knee. Semin Arthritis Rheum 2000; 30: 2-10.
40. Altman RD. Intra-articular sodium hyaluronate in osteoarthritis of the knee. Semin Arthritis Rheum 2000; 30: 11-18.
41. Dougados M. Sodium hyaluronate therapy in osteoarthritis: arguments for a potential beneficial structural effect. Semin Arthritis Rheum 2000; 30: 19-25.
42. Guidolin DD, Ronchetti IP, Lini E, et al. Morphological analysis of articular cartilage biopsies from a randomized. clinical study comparing the effects of 500-730 kDa sodium hyaluronate Hyalgan(R) and methylprednisolone acetate on primary osteoarthritis of the knee. Osteoarthritis Cartilage 2001; 9: 371-381.
43. Maheu E, Ayral X, Dougados M. A hyaluronan preparation (500-730 kDa) in the treatment of osteoarthritis: a review of clinical trials with Hyalgan(R). Int J Clin Pract 2002; 56: 804-813.
44. Barrett JP, Siviero P. Retrospective study of outcomes in Hyalgan(R)-treated patients with osteoarthritis of the knee. Clin Drug Invest 2002; 22: 87-97.
45. Miltner O, Schneider U, Siebert CH, et al. Efficacy of intraarticular hyaluronic acid in patients with osteoarthritis - a prospective clinical trial. Osteoarthritis Cartilage 2002; 10: 680-686.
46. Tascioglu F, Oner C. Efficacy of intra-articular sodium hyaluronate in the treatment of knee osteoarthritis. Clin Rheumatol 2003; 22: 112-117.
47. Uthman I, Raynauld JP, Haraoui B. Intra-articular therapy in osteoarthritis. Postgrad Med J 2003; 79: 449-453.
48. Kelly MA, Goldberg VM, Healy WL, et al. Osteoarthritis and beyond: a consensus on the past, present, and future of hyaluronans in orthopedics. Orthopedics 2003; 26: 1064-1079.
49. Hamburger MI, Lakhanpal S, Mooar PA, Oster D. Intra-articular hyaluronans: a review of product-specific safety profiles. Semin Arthritis Rheum 2003; 32: 296-309.
50. Kirwan J. Is there a place for intra-articular hyaluronate in osteoarthritis of the knee? Knee 2001; 8: 93-101.
51. Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 2002; 32: 10-37.
52. Balazs EA. Analgesic effect of elastoviscous hyaluronan solutions and the treatment of arthritic pain. Cells Tissues Organs 2003; 174: 49-62.
53. Fraser JRE, Kimpton WG, Pierscionek BK, Cahill RNP. The kinetics of hyaluronan in normal and acutely inflamed synovial joints - observations with experimental arthritis in sheep. Semin Arthritis Rheum 1993; 22: 9-17.
54. Zhu YX, Granick S. Biolubrication: hyaluronic acid and the influence on its interfacial viscosity of an antiinflammatory drug. Macromolecules 2003; 36: 973-976.
55. Ghosh S, Jassal M. Use of polysaccharide fibres for modem wound dressings. Indian J Fibre Textile Res 2002; 27: 434-450.
56. Risberg B. Adhesions: preventive strategies. Eur J Surg 1997; 163: 32-39.
57. Inoue M, Katakami C. The effect of hyaluronic-acid on corneal epithelial-cell proliferation. Invest Ophthalmol Vis Sci 1993; 34: 2313-2315.
58. Miyazaki T, Miyauchi S, Nakamura T, et al. The effect of sodium hyaluronate on the growth of rabbit cornea epithelial cells in vitro. J Ocul Pharmacol Ther 1996; 12: 409-415.
59. Stiebel-Kalish H, Gaton DD, Weinberger D et al. A comparison of the effect of hyaluronic acid versus gentamicin on corneal epithelial healing. Eye 1998; 12: 829-833.
60. Tani E, Katakami C, Negi A. Effects of various eye drops on corneal wound healing after superficial keratectomy in rabbits. Jpn J Ophthalmol 2002; 46: 488-495.
61. Vazquez JR, Short B, Findlow AH et al. Outcomes of hyaluronan therapy in diabetic foot wounds. Diabetes Res Clin Pract 2003; 59: 123-127.
62. Soldati D, Rahm F, Pasche P. Mucosal wound healing after nasal surgery. A controlled clinical trial on the efficacy of hyaluronic acid containing cream. Drugs Exp Clin Res 1999; 25: 253-261.
63. Ortonne JP. A controlled study of the activity of hyaluronic acid in the treatment of venous leg ulcers. J Dermatol Treatment 1996; 7: 75-81.
64. Cantor JO, Cerreta JM, Armand G, Turino GM. Aerosolized hyaluronic acid decreases alveolar injury induced by human neutrophil elastase. Proc Soc Exp Biol Med 1998; 217: 471-475.
65. Turino GM, Cantor JO. Hyaluronan in respiratory injury and repair. Am J Respir Crit Care Med 2003; 167: 1169-1175.
66. Simon A, Safran A, Revel A et al. Hyaluronic acid can successfully replace albumin as the sole macromolecule in a human embryo transfer medium. Fertil Steril 2003; 79: 1434-1438.
67. Gardner DK, Rodriegez-Martinez H, Lane M. Fetal development after transfer is increased by replacing protein with the glycosaminoglycan hyaluronan for mouse embryo culture and transfer. Hum Reprod 1999; 14: 2575-2580.
68. Vanos HC, Drogendijk AC, Fetter WPF, et al. The influence of contamination of culture-medium with hepatitis-B virus on the outcome of in vitro fertilization pregnancies. Am J Obstet Gynecol 1991; 165: 152-159.
69. Kemmann E. Creutzfeldt-Jakob disease (CJD) and assisted reproductive technology (ART) - quantification of risks as part of informed consent. Hum Reprod 1998; 13: 1777.
70. Suchanek E, Simunic V, Juretic D, Grizelj V. Follicular-fluid contents of hyaluronic-acid, follicle-stimulating-hormone and steroids relative to the success of in-vitro fertilization of human oocytes. Fertil Steril 1994; 62: 347-352.
71. Joly T, Nibart M, Thibier M. Hyaluronic-acid as a substitute for proteins in the deep-freezing of embryos from mice and sheep - an in vitro investigation. Theriogenology 1992; 37: 473-480.
72. Gardner DK, Lane M, Stevens J, Schoolcraft WB. Changing the start temperature and cooling rate in a slow-freezing protocol increases human blastocyst viability. Fertil Steril 2003; 79: 407-410.
73. Lane M, Maybach JM, Hooper K, et al. Cryo-survival and development of bovine blastocysts are enhanced by culture with recombinant albumin and hyaluronan. Mol Reprod Dev 2003; 64: 70-78.
74. Figueiredo F, Jones GM, Thouas GA, Trounson AO. The effect of extracellular matrix molecules on mouse preimplantation embryo development in vitro. Reprod Fertil Dev 2002; 14: 443-451.
75. Miyano T, Hirooka RE, Kano K et al. Effects of hyaluronic-acid on the development of 1-cell and 2-cell porcine embryos to the blastocyst stage in-vitro. Theriogenology 1994; 41: 1299-1305.
76. Kano K, Miyano T, Kato S. Effects of glycosaminoglycans on the development of in vitro matured and fertilized porcine oocytes to the blastocyst stage in vitro. Biol Reprod 1998; 58: 1226-1232.
77. Abeydeera LR. In vitro production of embryos in swine. Theriogenology 2002; 57: 257-273.
78. Jaakma U, Zhang BR, Larsson B, et al. Effects of sperm treatments on the in vitro development of bovine oocytes in semidefined and defined media. Theriogenology 1997; 48: 711-720.
79. Furnus CC, de Matos DG, Martinez AG. Effect of hyaluronic acid on development of in vitro produced bovine embryos. Theriogenology 1998; 49: 1489-1499.
80. Jang G, Lee BC, Kang SK, Hwang WS. Effect of glycosaminoglycans on the preimplantation development of embryos derived from in vitro fertilization and somatic cell nuclear transfer. Reprod Fertil Dev 2003; 15: 179-185.
81. Jarvinen K, Jarvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Dev Rev 1995; 16: 3-19.
82. Sasaki H, Yamamura K, Nishida K, et al. Delivery of drugs to the eye by topical application. Prog Retinal Eye Res 1996; 15: 583-620.
83. Gurny R, Ibrahim H, Aebi A et al. Design and evaluation of controlled release systems for the eye. J Control Release 1987; 6: 367-373.
84. Camber O, Edman P, Gurny R. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Curr Eye Res 1987; 6: 779-784.
85. Camber O, Edman P. Sodium hyaluronate as an ophthalmic vehicle - some factors governing its effect on the ocular absorption of pilocarpine. Curr Eye Res 1989; 8: 563-567.
86. Saettone MF, Monti D, Torracca MT, Chetoni P. Mucoadhesive ophthalmic vehicles - evaluation polymeric low-viscosity formulations. J Ocul Pharmacol 1994; 10: 83-92.
87. Saettone MF, Giannaccini B, Chetoni P, et al. Evaluation of high-molecular-weight and low-molecular-weight fractions of sodium hyaluronate and an ionic complex as adjuvants for topical ophthalmic vehicles containing pilocarpine. Int J Pharm 1991; 72: 131-139.
88. Bucolo C, Spadaro A, Mangiafico S. Pharmacological evaluation of a new timolol/pilocarpine formulation. Ophthalmic Res 1998; 30: 101-106.
89. Bucolo C, Mangiafico P. Pharmacological profile of a new topical pilocarpine formulation. J Ocul Pharmacol Ther 1999; 15: 567-573.
90. Herrero-Vanrell R, Fernandez-Carballido A, Frutos G, Cadorniga R. Enhancement of the mydriatic response to tropicamide by bioadhesive polymers. J Ocul Pharmacol Ther 2000; 16: 419-428.
91. Moreira CA, Armstrong DK, Jelliffe RW et al. Sodium hyaluronate as a carrier for intravitreal gentamicin - an experimental study. Acta Ophthalmol (Copenh) 1991; 69: 45-49.
92. Moreira CA, Moreira AT, Armstrong DK et al. In vitro and in vivo studies with sodium hyaluronate as a carrier for intraocular gentamicin. Acta Ophthalmol (Copenh) 1991; 69: 50-56.
93. Bernatchez SF, Tabatabay C, Gurny R. Sodium hyaluronate 0.25-percent used as a vehicle increases the bioavailability of topically administered gentamicin. Graefes Arch Clin Exp Ophthalmol 1993; 231: 157-161.
94. Gandolfi SA, Massari A, Orsoni JG. Low-molecular-weight sodium hyaluronate in the treatment of bacterial corneal ulcers. Graefes Arch Clin Exp Ophthalmol 1992; 230: 20-23.
95. Langer K, Mutschler E, Lambrecht G et al. Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery - Part III. Evaluation as drug delivery system for ophthalmic applications. Int J Pharm 1997; 158: 219-231.
96. Morimoto K, Yamaguchi H, Iwakura Y et al. Effects of viscous hyaluronate-sodium solutions on the nasal absorption of vasopressin and an analog. Pharmacol Res 1991; 8: 471-474.
97. Lim ST, Forbes B, Berry DJ, Martin GP, Brown MB. In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits. Int J Pharm 2002; 231: 73-82.
98. Drobnik J. Hyaluronan in drug delivery. Adv Drug Dev Rev 1991; 7: 295-308.
99. Sakurai K, Miyazaki K, Kodera Y et al. Anti-inflammatory activity of superoxide dismutase conjugated with sodium hyaluronate. Glycoconj J 1997; 14: 723-728.
100. Luo Y, Prestwich GD. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem 1999; 10: 755-763.
101. Luo Y, Ziebell MR, Prestwich GD. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 2000; 1: 208-218.
102. Prisell PT, Camber O, Hiselius J, Norstedt G. Evaluation of hyaluronan as a vehicle for peptide growth factors. Int J Pharm 1992; 85: 51-56.
103. Yerushalmi N, Arad A, Margalit R. Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug-delivery in wound-healing. Arch Biochem Biophys 1994; 313: 267-273.
104. Yerushalmi N, Margalit R. Hyaluronic acid-modified bioadhesive liposomes as local drug depots: effects of cellular and fluid dynamics on liposome retention at target sites. Arch Biochem Biophys 1998; 349: 21-26.
105. Peer D, Margalit R. Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes. Arch Biochem Biophys 2000; 383: 185-190.
106. Eliaz RE, Szoka FC. Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res 2001; 61: 2592-2601.
107. Peer D, Florentin A, Margalit R. Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. Biochim Biophys Acta-Biomembranes 2003; 1612: 76-82.
108. Morimoto K, Metsugi K, Katsumata H, et al. Effects of low-viscosity sodium hyaluronate preparation on the pulmonary absorption of rh-insulin in rats. Drug Dev Ind Pharm 2001; 27: 365-371.
109. Surendrakumar K, Martyn GP, Hodgers ECM, et al. Sustained release of insulin from sodium hyaluronate based dry powder formulations after pulmonary delivery to beagle dogs. J Control Release 2003; 91: 385-394.
110. Surini S, Akiyama H, Morishita M, et al. Polyion complex of chitosan and sodium hyaluronate as an implant device for insulin delivery. STP Pharm Sci 2003; 13: 265-268.
111. Takayama K, Hirata M, Machida Y et al. Effect of interpolymer complex-formation on bioadhesive property and drug release phenomenon of compressed tablet consisting of chitosan and sodium hyaluronate. Chem Pharmaceut Bull 1990; 38: 1993-1997.
112. Yun YH, Goetz DJ, Yellen P, Chen W. Hyaluronan microspheres for sustained gene delivery and site-specific targetting. Biomaterials 2004; 25: 147-157.
113. Kim A, Checkla DM, Dehazya P, Chen WL. Characterization of DNA-hyaluronan matrix for sustained gene transfer. J Control Release 2003; 90: 81-95.
114. Manuskiatti W, Maibach HI. Hyaluronic acid and skin: wound healing and aging. Int J Dermatol 1996; 35: 539-544.
115. Trommer H, Wartewig S, Bottcher R et al. The effects of hyaluronan and its fragments on lipid models exposed to UV irradiation. Int J Pharm 2003; 254: 223-234.
116. Duranti F, Salti G, Bovani B, Calandra M, Rosati ML. Injectable hyaluronic acid gel for soft tissue augmentation - a clinical and histological study. Dermatol Surg 1998; 24: 1317-1325.
117. Bergeret-Galley C, Latouche X, Illouz YG. The value of a new filler material in corrective and cosmetic surgery: DermaLive and DermaDeep. Aesthetic Plast Surg 2001; 25: 249-255.
118. Narins RS, Brandt F, Leyden J et al. A randomized, double-blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg 2003; 29: 588-595.
119. Lupton JR, Alster TS. Cutaneous hypersensitivity reaction to injectable hyaluronic acid gel. Dermatol Surg 2000; 26: 135-137.
120. Friedman PM, Mafong EA, Kauvar ANB, Geronemus RG. Safety data of injectable nonanimal stabilized hyaluronic acid gel for soft tissue augmentation. Dermatol Surg 2002; 28: 491-494.
121. Lin K, Bartlett SP, Matsuo K et al. Hyaluronic acid-filled mammary implants - an experimental study. Plast Reconstr Surg 1994; 94: 306-315.
122. Brown MB, Marriott C, Martin GP. A study of the transdermal drug delivery properties of hyaluronan. In: Willoughby DA, ed. Hyaluronan in Drug Delivery. Royal Society of Medicine Press, London, 1995: 53-71.
123. Fieldman SR, Fleischer AB, McConnell C. Most common dermatological problems identified by internists. Arch Intern Med 1998; 158: 726-730.
124. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: S8-S10.
125. Del Rosso JQ. New and emerging topical approaches for actinic keratoses. Cutis 2003; 72: 273.
126. Jarvis B, Figgitt DP. Topical 3% diclofenac in 2.5% hyaluronic acid gel - a review of its use in patients with actinic keratoses. Am J Clin Dermatol 2003; 4: 203-213.
127. Schartz RA. The actinic keratoses. A perspective and update. Dermatol Surg 1997; 23: 1009-1019.
128. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: S23-S24.
129. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: S4-S7.
130. Harvey I, Frankel S, Marks R, et al. Non-melanoma skin cancer and solar keratoses. 1. Methods and descriptive results of the South Wales skin cancer study. Br J Cancer 1996; 74: 1302-1307.
131. Rivers JK, Mclean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997; 133: 1239-1242.
132. McKewan LE, Smith JG. Topical diclofenac/hyaluronan gel in the treatment of solar keratoses. Aust J Dermatol 1997; 38: 187-189.
133. Jarvis B, Figgitt DP. Topical 3% diclofenac in 2.5% hyaluronic acid gel - a review of its use in patients with actinic keratoses. Am J Clin Dermatol 2003; 4: 203-213.
134. Wolf JE, Taylor JR, Tschen E, Kang SW. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-713.
135. Panie WR. Regression of head and neck carcinoma with a prostaglandin-synthesis inhibitor. Arch Otolaryngol 1981; 107: 658-663.
136. Braun DP, Taylor SG, Hams JE. Modulation of immunity in cancer patients by prostaglandin antagonists. In: Alan R, ed. Immunity to Cancer II. Liss Inc., New York, 1989:439.
137. Falk RE, Mikkelsaar S, Asculai S, et al. Evaluation of prostaglandin (PGE) inhibitors combined with cytodestructive therapy in advanced neoplasia. Proceedings of the International Clinical Hyperthermia Meeting, Lyon, France, 1992.
138. Brunda MJ, Herberman RB, Holden HI. Inhibition of immune natural killer cell activity by Prostaglandins. J Immunol 1980; 124: 2682-2687.
139. 2-mediated suppression. Surgery 1982; 92: 528-532.
140. 2 and norhydroguaiaretic acid, a lipooxygenase inhibitor. Cancer Immunol Immunother 1988; 27: 133-136.
141. Brown MB, Forbes B, Martin GP. The use of hyaluronan in topical drug delivery. In: Kennedy J, Phillips GO, Williams PA, Hascall V, eds. Hyaluronan: Biomedical, Medical and Clinical Aspects. Woodhead Publishers, Cambridge, 2002: 249-256.
142. Brown MB, Marriott C, Martin GP. The effect of hyaluronan on the in vitro deposition of diclofenac within the skin. Int J Tissue Reactions-Exp Clin Aspects 1995; 17: 133-140.
143. Brown MB, Martin GP. Comparison of the effect of hyaluronan and other polysaccharides on drug skin partitioning. Int J Pharm 2001; 225: 113-121.
144. McEwan LE, Smith JG. Topical diclofenac/hyaluronan gel in the treatment of solar keratoses. Aust J Dermatol 1997; 38: 187-189.
145. Brown MB, Ingham S, Moore A, et al. A preliminary study of the effect of hyaluronan in drug delivery. In: Willoughby DA, ed. Hyaluronan in Drug Delivery. Royal Society of Medicine Press, London, 1995: 48-52.
146. Nazir T, Martin GP, Brown MB. Dermal delivery of cyclosporin A entrapped liposomal gels - preformulation Franz cell diffusion studies using silastic membranes. STP Pharm Sci 2001; 3(Suppl.): 1429.
147. Brown MB, Moore A. The effects of a novel formulation of cyclosporin on antibody and cell-mediated immune reactions in the pleural cavity of rats. In: Willoughby DA, ed. Hyaluronan in Drug Delivery. Royal Society of Medicine Press, London, 1996: 121-131.
148. Lin W, Maibach HI. Percutaneous absorption of diclofenac in hyaluronic acid gel: in vitro study in human skin. In: Willoughby D, ed. Hyaluronan in Drug Delivery. Royal Society of Medicine Press, London, 1996: 167-174.
149. Amr SK. The effect of homogenised skin on the activity of licosamde antibiotics. Proceedings of Millennium Congress of Pharmaceutical Science, San Francisco, USA, 2000.
150. Brown TJ, Alcorn D, Fraser JRE. Absorption of hyaluronan applied to the surface of intact skin. J Invest Dermatol 1999; 113: 740-746.
151. Alam CAS, Seed MP, Willoughby DA. Angiostasis and vascular regression in chronic granulomatous inflammation-induced by diclofenac in combination with hyaluronan in mice. J Pharm Pharmacol 1995; 47: 407-411.
152. Seed MP, Brown JR, Freemantle CN et al. The inhibition of colon-26 adenocarcinoma development and angiogenesis by topical diclofenac in 2.5% hyaluronan. Cancer Res 1997; 57: 1625-1629.
153. Bucks D, Maibach HI. Occlusion does not uniformly enhance penetration in vivo. In: Bronaugh RL, Maibach HL, eds. Percutaneous Absorption; Drugs, Cosmetics, Mechanisms, Methodology. Marcel Dekker, New York, 1999: 81-108.
154. Whistler RL. Introduction to industrial gums. In: Whistler RL, BeMiller JN, eds. Industrial Gums: Polysaccharides and Their Derivatives. Academic Press, San Diego, 1993: 1-3.
155. Cowman MK, Liu J, Hittner DM, Kim JS. Hyaluronan interactions: salt, water, ions. In: Laurent TC, ed. The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives. Portland Press, London, 1998: 17-25.
156. Gustafson S. Hyaluronan in drug delivery. In: Laurent TC, ed. The Chemistry, Biology and Medical Applications of Hyaluronan and its Derivatives. Portland Press, London, 1998: 291-304.
157. Scott JE. Secondary structures in hyaluronan solution: chemical and biological implications. In: Everend D, Whelan J, eds. The Biology of Hyaluronan. John Wiley, Chichester, 1989: 6-16.
158. Mabuchi K, Obara T, Ikegami K, et al. Molecular weight independence of the effect of additive hyaluronic acid on the lubricating characteristics in synovial joints with experimental deterioration. Clin Biomechanics 1999; 14: 352-356.